23andMe
American personal genomics company
Follow 23andMe on Notably News to receive short updates to your email — rarely!
| May 19 2025 | Regeneron agreed to acquire 23andMe for $256 million during bankruptcy proceedings. |
| March 31 2025 | Trading for 23andMe shares was suspended and the stock was delisted from Nasdaq. |
| March 2025 | Wojcicki made a third offer of 41 cents per share to take the company private. |
| March 2025 | 23andMe filed for Chapter 11 bankruptcy, and the founder and CEO resigned. California Attorney General Rob Bonta issued a privacy consumer alert, advising Californians to request deletion of their genetic data. |
| March 23 2025 | 23andMe filed for Chapter 11 bankruptcy protection in Delaware. Anne Wojcicki announced she would step down as CEO, to be replaced by CFO Joe Selsavage. |
| January 2025 | 23andMe declared the need for additional liquidity and began exploring strategic alternatives, including a potential sale of the company. |
| 2024 | 23andMe experienced severe financial difficulties, losing 98% of its $6 billion market value. The company's financial instability raised significant concerns among its 15 million customers about the security and potential future use of their stored DNA data. |
| November 2024 | The company conducted layoffs. |
| November 2024 | 23andMe conducted layoffs. |
| September 2024 | Seven independent board members resigned from 23andMe. |
| July 2024 | Anne Wojcicki announced her intention to take 23andMe private by purchasing outstanding shares at 40 cents each. |
| February 2024 | 23andMe announced they had genotyped more than 14,000,000 individuals, marking significant growth from their previous milestone of 3,000,000 genotyped individuals. |
| October 2023 | A significant data breach occurred at 23andMe, resulting in the theft of sensitive information from approximately 7 million users. Hackers specifically targeted Ashkenazi Jews and users of Chinese descent, stealing names, addresses, and genetic data, which was subsequently put up for sale online. |
| 2021 | Became a publicly traded company through a SPAC merger, achieving a market capitalization of US$6 billion. |
| December 2021 | 23andMe acquired Lemonaid Health, a digital healthcare company, for $400 million to enhance healthcare risk and treatment information. As part of the acquisition, Paul Johnson, Lemonaid Health's CEO and co-founder, became the COO of 23andMe's consumer business. |
| October 2021 | 23andMe announced the acquisition of Lemonaid Health, a telehealth company, for $400 million. |
| June 17 2021 | 23andMe completed its merger with VG Acquisition Corp and began trading on Nasdaq under the ticker symbol 'ME'. |
| April 2021 | The 23andMe COVID-19 blood type risk study was officially published, detailing findings that individuals with type O blood were 13–26% less likely to test positive when exposed to the virus. |
| February 2021 | 23andMe announced a merger with Sir Richard Branson's VG Acquisition Corp in a $3.5 billion transaction. |
| October 1 2020 | 23andMe launched a new subscription service called '23andMe+' for $29/year, offering additional health and pharmacogenetic reports to customers who completed genotyping on version 5 of their microarray chip. |
| July 2020 | 23andMe and GlaxoSmithKline announced their first joint clinical trial for cancer treatment. |
| June 2020 | 23andMe published results from a COVID-19 blood type risk study, suggesting that people with type O blood may be at lower risk of catching the virus. The study analyzed data from over 750,000 participants, finding they were 9–18% less likely to contract COVID-19. |
| January 2020 | 23andMe announced layoffs of about 100 employees in its consumer testing division. |
| 2019 | 23andMe moved its headquarters from Mountain View to a larger location in Sunnyvale. |
| July 25 2018 | 23andMe announced a partnership with GlaxoSmithKline, allowing the pharmaceutical company to use test results from 5 million customers to design new drugs, with GlaxoSmithKline investing $300 million. |
| May 25 2018 | 23andMe begins compliance with the General Data Protection Regulation (GDPR) in the European Union, implementing new rules to help individuals control their personal data collection, usage, and storage. |
| April 2018 | 23andMe announced the Populations Collaboration Program to establish formal collaborations with researchers investigating underrepresented countries. |
| March 2018 | The FDA approved 23andMe's direct-to-consumer test for three specific BRCA mutations associated with increased risk of breast, ovarian, and prostate cancer in people of Ashkenazi descent. |
| February 2018 | 23andMe announced an expansion of ancestry reporting to include specific countries and increased the number of regions by 120. The company also launched the Global Genetics Program to increase genomic data from 61 underrepresented countries. |
| April 2017 | The FDA approved 23andMe's applications for ten genetic risk tests, including tests for late-onset Alzheimer's disease, Parkinson's disease, and several other conditions. |
| October 2016 | 23andMe launched the African Genetics Program with a grant from the US National Institutes of Health to increase genomic data on sub-Saharan Africans. |
| October 2016 | 23andMe launched an ancestry-only version at a lower price of $99 with an option to upgrade to include health results. |
| 2015 | 23andMe raised $115 million in a Series E offering, increasing total capital to $241 million. |
| 2015 | Health-related results for US customers were reinstated after FDA regulatory review. |
| October 21 2015 | 23andMe announced they would resume marketing carrier tests in the US. |
| October 21 2015 | 23andMe resumed providing health information in the form of carrier status and wellness reports with FDA approval. |
| February 2015 | The FDA cleared 23andMe's carrier test for Bloom syndrome, indicating that similar future applications would not require additional review. |
| December 2014 | 23andMe started offering genetic testing services in the United Kingdom with ancestry and health-related components. |
| October 2014 | 23andMe began selling genetic testing products with ancestry and health-related components in Canada. |
| November 22 2013 | Due to FDA restrictions, 23andMe began selling only raw genetic data and ancestry-related results in the US. |
| November 22 2013 | Health-related results for US customers were suspended pending FDA regulatory review. |
| 2012 | 23andMe raised $50 million in a Series D venture round, nearly doubling its previous capital. |
| September 2012 | 23andMe submitted additional FDA clearance applications in September. |
| July 2012 | 23andMe first submitted applications for FDA clearance in July. |
| June 2012 | 23andMe eliminated its unpopular monthly subscription model for research updates. |
| 2011 | Linda Avey co-founded Curious, Inc. |
| 2010 | The FDA notified 23andMe and other genetic testing companies that their genetic tests are considered medical devices requiring federal approval for marketing. |
| 2010 | The company recombined its previously split product lines and introduced a monthly subscription fee for updates based on new medical research findings. |
This contents of the box above is based on material from the Wikipedia article 23andMe, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.